"Medical quick reading society" Roche ADC medicine Hercules is approved by BMS to launch new biomedical talents

Novel coronavirus infection was diagnosed in 24324 cases as of 24: February 4th The new pneumonia diagnosis and treatment plan (trial version fifth) was released Gillide 2019 financial report: hepatitis C decline, hepatitis B Vemlidy gradually became new force, Bristol Myers Squibb launched a new biomedical innovation, and brother Wei's "pulmonary hypertension" indication is being approved in China As of 24:00 on February 4, the national health and Health Commission has received 24324 confirmed cases (1 case in Hainan Province) reported by 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, 3219 serious cases, 490 dead cases, 892 discharged cases cured (1 case in Hainan Province and 1 case in Hubei Province), and 23260 suspected cases (National Health and Health Commission) The novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) released on the forenoon of 5, compared with the fourth edition, focused on three aspects: first, the characteristics of epidemiology were more clear, and the description of clinical manifestations was more detailed Second, it is more refined in the clinical classification of cases Compared with the fourth edition, it has increased light, that is to say, it has now become light, common, heavy and critical, so as to strengthen the guidance of clinical classification, better lock cases and improve the treatment level Third, the treatment methods and means are more abundant, not only symptomatic and supportive treatment, including oxygen therapy, are classified in detail, which provides a basis for more guidance and operability in the clinical treatment process (National Health and Health Commission) 5, the novel coronavirus infection prevention and control of the National Health Protection Committee issued the notice of the home quarantine medical observation infection prevention and control guidelines (Trial Implementation), and gave detailed guidance to the infection prevention and control of the home quarantine medical observers (National Health and Health Commission) Today, Bristol Myers Squibb（ On April 4, Geely announced its 2019 results, with a total annual revenue of US $22.449 billion, an increase of 1.5% compared with 2018 Among them, the sales revenue of AIDS products reached US $16.438 billion, an increase of 12% compared with 2018, and the proportion in the company's total revenue increased to 73.32%, which is Geely's core business segment (medicine cube) Novartis achieved a total revenue of US $47.445 billion in 2019, up 6% year on year Among them, the revenue of innovative medicine business reached US $37.714 billion, an increase of 8% year-on-year; the revenue of Sandoz, the generic medicine business unit, was US $9.731 billion, down 1% The financial report also showed that Novartis China market achieved double-digit growth throughout the year and is expected to double its performance in China in 2024 (e drug manager) On March 3, Shanghai Laishi company received the notice on emergency requisition of production capacity issued by Shanghai Municipal Economic and Information Technology Commission, which was authorized by Shanghai Municipal People's government, in accordance with Article 11, paragraph 2, Article 12, Article 52, Article 66 of the emergency response law of the people's Republic of China and Article 35 of the Shanghai implementation measures It is hereby decided to expropriate the medical protective articles, drugs, devices and production capacity of your unit (Sina Medical News) Roche pharmaceutical China announced that the State Food and drug administration has officially approved the innovative targeted drug hesaile ® (English trade name: kadcyla ®, general name: enmetrastuzumab) The single drug is applicable to the adjuvant treatment of HER2 positive early breast cancer patients who still have invasive lesions after the new adjuvant treatment based on taxanes combined with trastuzumab (cypress blue) NIH announced Wednesday that its National Institute of allergy and infectious diseases has stopped a clinical trial of HIV vaccination in South Africa The reason is that the data and safety monitoring committee found in its mid-term review that the vaccine programme for the study did not prevent HIV But the Commission did not express any concerns about the safety of vaccination participants (Sina Medical News) According to the announcement issued by Beida pharmaceutical, equinox Sciences, LLC, a holding subsidiary, signed an exclusive license agreement with eyepoint pharmaceuticals, Inc (NASDAQ: eypt), which authorizes eypt to develop the tyrosine kinase inhibitor vorolanib (CM082) by local injection to treat wet age-related macular degeneration and other eye diseases (Sina Medical News) Northeast Pharmaceutical Co., Ltd and its wholly-owned subsidiary Shenyang No.1 Pharmaceutical Co., Ltd respectively obtained the hygiene license for disinfection product manufacturing enterprises issued by Shenyang Municipal Health Committee and the registration certificate for medical devices of the people's Republic of China issued by Liaoning Provincial Drug Administration, Northeast Pharmaceutical Co., Ltd announced Thursday (Sina Medical News) On April 4, Hunan Yangpu, a subsidiary of Guangzhou Yangpu medical company, received the medical device registration certificate issued by Hunan drug administration It is reported that the medical surgical mask is an emergency approval registration with a validity period of 8 months In addition, another product of Hunan Yangpu - Emergency registration of medical protective mask is still in progress (Sina Medical News) April 4, Puli pharmaceutical announced that the company had recently received a notice that the registration application of 500 mg Ganciclovir Sodium for injection submitted to the Cyprus pharmaceutical regulatory authority had been approved (Sina Medical News) On March 3, CDE formula proposed a batch of priority review and approval lists, including Pfizer's "sildenafil citrate tablets", which were included on the basis of rare diseases and had previously been included in the list of clinically urgent overseas new drugs (Insight database) On March 3, CDE official website showed that Pfizer chlorobenzoic acid soft capsule (tafamidis) was included in the planned priority review procedure according to 4 rare diseases in the priority review scope (2) (Sina Medical News) Youshibi recently announced that the Japanese regulatory authorities have approved cimzia (Chinese trade name: ximinijia ®, general name: certolizumab pegol, peserizumab injection) for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythroderma psoriasis, which are not effective in the existing treatment (Biovalley) On March 3, China biopharma announced that its subsidiary tdi01, an innovative drug for fibrosis treatment independently developed by Beijing Taide pharmaceutical, has submitted an application for a new drug for trial use to the FDA and has been accepted (medicine cube) Recently, gma301, the original monoclonal antibody new drug of Hongyun Huaning biomedical Co., Ltd., has been approved by the US FDA for clinical trials This is another milestone in the globalization of Hongyun Huaning new drug research and development, which is approved by the authoritative drug regulatory agency after the drug review center of China National Drug Administration (medicine cube)